Literature DB >> 12663448

A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production.

David Hamilton1, Jian Hui Wu, Moulay Alaoui-Jamali, Gerald Batist.   

Abstract

Gamma-glutamylcysteine synthetase (gamma-GCS) catalyzes the first and rate-limiting step in glutathione (GSH) biosynthesis: the adenosine triphosphate (ATP)-dependent ligation of glutamate and cysteine. gamma-GCS consists of a catalytic (gamma-GCSH) and modifier (gamma-GCSL) subunit. Hereditary deficiency of gamma-GCS has been reported in a small number of patients and is associated with low erythrocyte levels of gamma-GCS and GSH leading to hemolytic anemia. Here we report a novel gamma-GCSH mutation, isolated from the cDNA of 2 related patients diagnosed with gamma-GCS deficiency. Each was found to be homozygous for a C>T missense mutation at nucleotide 379, encoding for a predicted Arg127Cys amino acid change. Computerized structure modeling identified that the mutated amino acid lies within a cleft on the protein surface of gamma-GCSH, and the border of this cleft was shown to contain Cys249, an evolutionarily conserved residue that has been proven to lie near the binding site of gamma-GCSH. Transfection studies showed that the mutation is associated with decreased GSH production, and binding studies using purified recombinant protein showed that the mutant protein has markedly decreased enzymatic activity compared to wild type.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663448     DOI: 10.1182/blood-2002-11-3622

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Mathematical modeling of the methionine cycle and transsulfuration pathway in individuals with autism spectrum disorder.

Authors:  Troy Vargason; Daniel P Howsmon; Stepan Melnyk; S Jill James; Juergen Hahn
Journal:  J Theor Biol       Date:  2016-12-29       Impact factor: 2.691

2.  Enzymatic defects underlying hereditary glutamate cysteine ligase deficiency are mitigated by association of the catalytic and regulatory subunits.

Authors:  Melanie Neely Willis; Yilin Liu; Ekaterina I Biterova; Melanie A Simpson; Heejeong Kim; Jaekwon Lee; Joseph J Barycki
Journal:  Biochemistry       Date:  2011-06-29       Impact factor: 3.162

3.  An ethnic-specific polymorphism in the catalytic subunit of glutamate-cysteine ligase impairs the production of glutathione intermediates in vitro.

Authors:  Truc M Le; Alecia S Willis; Frederick E Barr; Gary R Cunningham; Jeffrey A Canter; Sarah E Owens; Rachel K Apple; George Ayodo; David Reich; Marshall L Summar
Journal:  Mol Genet Metab       Date:  2010-06-09       Impact factor: 4.797

Review 4.  Glutathione defense mechanism in liver injury: insights from animal models.

Authors:  Y Chen; H Dong; D C Thompson; H G Shertzer; D W Nebert; V Vasiliou
Journal:  Food Chem Toxicol       Date:  2013-07-12       Impact factor: 6.023

Review 5.  Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase.

Authors:  Christopher C Franklin; Donald S Backos; Isaac Mohar; Collin C White; Henry J Forman; Terrance J Kavanagh
Journal:  Mol Aspects Med       Date:  2008-09-06

Review 6.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

Review 7.  Glutathione analogues in cancer treatment.

Authors:  David Hamilton; Gerald Batist
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

8.  Genomic analyses reveal a conserved glutathione homeostasis pathway in the invertebrate chordate Ciona intestinalis.

Authors:  Gerardo M Nava; David Y Lee; Javier H Ospina; Shi-Ying Cai; H Rex Gaskins
Journal:  Physiol Genomics       Date:  2009-05-26       Impact factor: 3.107

9.  Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.

Authors:  Shanshan Pei; Mohammad Minhajuddin; Kevin P Callahan; Marlene Balys; John M Ashton; Sarah J Neering; Eleni D Lagadinou; Cheryl Corbett; Haobin Ye; Jane L Liesveld; Kristen M O'Dwyer; Zheng Li; Lei Shi; Patricia Greninger; Jeffrey Settleman; Cyril Benes; Fred K Hagen; Joshua Munger; Peter A Crooks; Michael W Becker; Craig T Jordan
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

10.  Manipulation of cellular GSH biosynthetic capacity via TAT-mediated protein transduction of wild-type or a dominant-negative mutant of glutamate cysteine ligase alters cell sensitivity to oxidant-induced cytotoxicity.

Authors:  Donald S Backos; Chad N Brocker; Christopher C Franklin
Journal:  Toxicol Appl Pharmacol       Date:  2009-11-13       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.